There is one clinical trial.
This study seeks to assess the impact of physical and pulmonary rehabilitation on patients who have been diagnosed with COVID-19 in the short and long term in hopes of establishing a best practices protocol for treatment of future patients with this disease.
Description: Validated test demonstrating functional gait capacity and endurance; measuring change in capacity over time in 6 month increments.Measure: Change in 6 Minute Walk Test Time: From 6 to 24 months post diagnosis
Description: Validated questionnaire assessing function and quality of life for patients with pulmonary function issuesMeasure: Change in Short Form 35 (SF-36) Questionnaire Time: From 6 to 24 months post diagnosis
Description: Use of grip dynamometer and isokinematic lower extremity testing to determine muscle capacityMeasure: Change in Strength testing Time: From 6 to 24 months post diagnosis
Description: Measures lung output capacityMeasure: Change in Peak Flow Meter Test Time: From 6 to 24 months post diagnosis
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports